STABILITY-INDICATING REVERSED-PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY METHOD FOR THE SIMULTANEOUS ESTIMATION OF DARUNAVIR AND RITONAVIR

  • Sindu Priya D AU college of Pharmaceutical sciences, Andhra University
  • Gowri Sankar D
  • Masthanamma Sk

Abstract

ABSTRACT
Objective: The main objective of the proposed study was to develop and validate a new stability indicating reverse phase high performance liquid
chromatography method for the simultaneous estimation of darunavir (DRV) and ritonavir (RTV).
Methods: The method was optimized using Atlantis C18 column (50 mm×4.6 mm, 5 µm, Waters Corporation, Milford, USA). Acetonitrile and water
were used as mobile phase in the proportion of 60:40. The flow rate was 0.8 ml/minutes and the effluent was monitored at 230 nm.
Results: The retention time of DRV and RTV was 3.15 minutes and 4.59 minutes, respectively. The method was precise as it showed a % relative
standard deviation of <2%. The percentage recoveries of both the drugs DRV and RTV were 99.8-100.01% and 99.5-99.97%, respectively. The
linearity of DRV and RTV was in the range of 40-120 and 4-20 µg/ml, respectively. Calibration curve showed good linearity and range. The correlation
coefficient of DRV and RTV was 0.999 each. Moreover, the results obtained for limit of quantification, limit of detection, robustness, and ruggedness
were well within the acceptance criteria.
Conclusion: The proposed method was found to be simple, rapid, accurate, precise, and stability indicating. It was found to be economical and suitable
for simultaneous determination of DRV and RTV which is can also be applied for pharmaceutical dosage form.
Keywords: Darunavir, Ritonavir, Reversed-phase-high performance liquid chromatography, Simultaneous estimation, Forced degradation.

Author Biography

Sindu Priya D, AU college of Pharmaceutical sciences, Andhra University

Senior Resaerch Fellow, 

Department of Pharmaceutical Analysis and Quality assrance

 

References

REFERENCES
1. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/
label/2012/020945s033lbl.pdf.
2. Available from: http://www.investor.jnj.com/releasedetail.
cfm?releaseid=536723.
3. Babu GR, Rao AL, Rao JV. Development and validation of novel HPLC
method for estimation of darunavir in pharmaceutical formulations. Int
J Res Pharm Chem 2013;3(2):438-43.
4. Salunke JM, Singh S, Malwad S, Chavhan VD, Pawar MS, Patel C, et al.
A validated RP HPLC method for simultaneous estimation of lopinavir
and ritonavir in combined dosage form. Sch Res Libr 2013;5(4):1-6.
5. Reddy BV, Jyothi G, Reddy BS, Raman NV, Chander KS, Rambabu C.
Stability-indicating HPLC method for the determination of darunavir
ethanolate. J Chromatogr Sci 2013;51(5):471-6.
6. Available from: http://www.ich.org/fileadmin/Public_Web_Site/ICH_
Products/Guidelines/Quality/Q2_R1/Step4/Q2_R1__Guideline.pdf.
7. Stability Testing: Photostability Testing of New Drug Substances and
Products q1b, ICH Harmonised Tripartite Guideline, Current Step 4
Version Dated 6 November; 1996.
Statistics
324 Views | 256 Downloads
Citatons
How to Cite
D, S. P., G. Sankar D, and M. Sk. “STABILITY-INDICATING REVERSED-PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY METHOD FOR THE SIMULTANEOUS ESTIMATION OF DARUNAVIR AND RITONAVIR”. Asian Journal of Pharmaceutical and Clinical Research, Vol. 9, no. 8, Oct. 2016, pp. 66-71, doi:10.22159/ajpcr.2016.v9s2.11494.
Section
Original Article(s)